Foot and mouth disease concentrate bulk antigen serotype A- inactivated (for export purpose)

recombinant porcine cysticercosis vaccine Each dose of 1mL contains: taenia solium onchosphere antigen (TSOL 18) ≥ 150µg, thiomersal B.P. ≤ 0.02% w/v as preservative and mineral oil and phosphate buffer q.s to 1mL

Brand name is Gyroflox. It is used in the treatment of diseases associated with bacteria susceptible to enrofloxacin.

Brand name is Gyroflox. It is used in the treatment of diseases associated with bacteria susceptible to enrofloxacin.

Fenbendazole bolus

Fenbendazole bolus

composition: FMD antigen serotype -A, thiomersal ≤ 0.01% w/v added as preservative, adult bovine serum 0.5% added as an stabilizer and virus maintenance medium Q.s

composition: FMD antigen serotype -O, thiomersal ≤ 0.01% w/v added as preservative, adult bovine serum 0.5% added as an stabilizer and virus maintenance medium Q.s

Ivermectin oral tablet is used to treat parasitic infections of your intestinal tract, skin, and eyes.

Ivermectin oral tablet is used to treat parasitic infections of your intestinal tract, skin, and eyes.

Canine distemper (living), canine adeno virus (Living), canine parvo virus (living), canine adeno virus (inactivated) and leptospirosis vaccine, inactivated Freeze dried component Vial 1 coposition: Each single dose contains canine distemper virus (living ) B.P (Vet.) ≥ 10³ TCID50 [Propagated on vero cel...

Freeze dried component vial 1: Each single dose contains: canine distemper virus (living) B.P (Vet.) ≥ 103 TCID 50 [propagated on vero cells]; canine adeno virus (living) B.P (Vet.) ≥ 103 TCID 50 [propagated on MDCK cells]; canine parvo virus (living) B.P (Vet.) ≥ 103 TCID 50 (≥ 128HA units) [propagated on...

Indian Immunologicals Limited, in collaboaration with Griffith University, Australia is going to commence research for developing a vaccine for Corona virus, the pandemic which has infected more than two million and killed about 250,00 people across the world. 

Even WHO has considered the same in its latest draft landscape of COVID 19 vaccine candidates dated 30th April, 2020.